{
  "docId": "019de072-65f6-7273-bf5f-9dfce8e99600",
  "docSlug": "b41af86b98765dd2459355c3b31d267e",
  "documentTitle": "OmniAb | SPAC Presentation Deck | 35 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 35,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "The slide uses a combination of market sizing, comparative success rates, and regulatory approval trends to justify the business opportunity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-65f6-7273-bf5f-9dfce8e99600/11",
  "deckHref": "/decks/019de072-65f6-7273-bf5f-9dfce8e99600",
  "deckJsonHref": "/decks/019de072-65f6-7273-bf5f-9dfce8e99600.json",
  "deckAnchorHref": "/decks/019de072-65f6-7273-bf5f-9dfce8e99600#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.44,
        "y": 0.68
      },
      "kind": "callout",
      "text": "Historical success rates for antibody classes is nearly twice the rate of small molecules",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02663518-2ac5-461e-8191-c2d0effcc39e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.35,
        "x": 0.62,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Acceleration of Regulatory Approvals (FDA and EMA)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84d0285c-c066-4e0e-8af0-fed7a4b70002",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Sources: 2020 Sales of Recombinant Therapeutic Antibodies... (1) Defined as composite success rate of clinical development from Phase I trials to regulatory submission.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "344d405f-70ab-4dbf-aded-e2e0c8047fa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.04,
        "y": 0.43
      },
      "kind": "list",
      "text": "Increasing Antibody Market: $236B in antibody sales by 2025; 41 blockbuster antibodies in 2020; Five best-selling antibodies had ~$55B of sales in 2020",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "541000e9-ba61-4989-a10f-6549a0d85779",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.55,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Existing Industry limitations: Current approaches burdened with critical disadvantages – lack of antibody diversity, lengthy timelines, excess costs and lack of flexibility",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ac47c50-d3e3-4f9f-a572-9b35979912c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.42,
        "x": 0.04,
        "y": 0.67
      },
      "kind": "table",
      "text": "Type of Drug | Clinical Success Rates(1) | Small Molecules | 6.2% | Biologics/Antibodies | 11.5%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3864913b-df9b-4693-a38a-84d83cf8a00d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "HIGHER SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1822379-b86f-44f2-955f-b5233ae4fd89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "ANTIBODIES AND INDUSTRY DEMAND",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b916b5c-12d6-49e0-8b8f-a91b10b3884b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "argument-from-analogy",
      "slug": null,
      "matchId": "9a0b74b8-6fa9-4b3a-8a14-9ce75bb9305d",
      "evidence": "Comparing success rates of biologics vs small molecules to justify market demand",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 11,
      "beatId": "33b84b9b-28c6-470a-87d1-82e55ef031ed",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents the problem on page 11",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 11,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "9565f332-5dd7-4de8-9671-88ecf08de979",
      "evidence": "The document presents the why now on page 11",
      "position": 0,
      "objective": "Why now?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}